Network origin in Robert Gundel first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 16 | |
Arius Research, Inc.
 Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada.
4
| Extinct | Biotechnology | 4 |
| Public Company | Pharmaceuticals: Major | 4 | |
XOMA (US) LLC
 XOMA (US) LLC Pharmaceuticals: MajorHealth Technology XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Robert Gundel via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| NYMOX PHARMACEUTICAL CORPORATION | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| VERNALIS | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| APTOSE BIOSCIENCES INC. | Pharmaceuticals: Major | Chairman Director of Finance/CFO Director/Board Member | |
D. E. Shaw & Co. LP
 D. E. Shaw & Co. LP Investment ManagersFinance D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to several affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants. | Investment Managers | Corporate Officer/Principal | |
| TELESTA THERAPEUTICS INC | Pharmaceuticals: Other | Chairman Director/Board Member | |
| SERNOVA CORP. | Biotechnology | Director/Board Member Chairman | |
| TYHEE GOLD CORP. | Precious Metals | Director/Board Member Director/Board Member | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Cita NeuroPharmaceuticals, Inc.
 Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Translational Medicine India, Inc.
 Translational Medicine India, Inc. Miscellaneous Commercial ServicesCommercial Services Translational Medicine India, Inc. provides clinical research solutions. It offers a novel therapeutic with biomarkers and early stage clinical trials for researchers. The company is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Chairman | |
Voleon Capital Management LP
 Voleon Capital Management LP Investment ManagersFinance Voleon Capital Management LP, do-business as The Voleon Group (Voleon), is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Berkeley, California. The firm was co-founded in 2007 by Michael Kharitonov and Jon McAuliffe. Voleon provides advisory services on a discretionary basis to pooled investment vehicles, which are private investment funds. | Investment Managers | Chief Executive Officer | |
Pelican Therapeutics, Inc.
 Pelican Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Pelican Therapeutics, Inc. operates as an immuno-oncology company. It develops biological agents that represents the next generation of tumor necrosis factor (TNF) based immunotherapy. The company was founded by Jeffrey Wolf and Josiah C. Hornblower on March 6, 2017 and is headquartered in Dallas, TX. | Hospital/Nursing Management | Founder Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree Graduate Degree Undergraduate Degree Graduate Degree | |
| Stanford University | College/University | Doctorate Degree | |
Bain & Co., Inc.
 Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Williams Creek Gold Ltd.
 Williams Creek Gold Ltd. Precious MetalsNon-Energy Minerals Williams Creek Gold Ltd. engages in the exploration of mineral properties. The company was founded on June 19, 1946 and is headquartered in Vancouver, Canada. | Precious Metals | Chairman Chief Executive Officer | |
| Xmark Fund Ltd. | Chief Investment Officer | ||
| McGill University | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree | |
| The University of Chicago | College/University | Undergraduate Degree Masters Business Admin | |
| Union College (New York) | College/University | Undergraduate Degree Undergraduate Degree | |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| The University of Waterloo | College/University | Graduate Degree Graduate Degree | |
| University of Western Ontario | College/University | Undergraduate Degree | |
| McMaster University | College/University | Doctorate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree | |
| University of Windsor | College/University | Masters Business Admin | |
Muscular Dystrophy Association, Inc.
 Muscular Dystrophy Association, Inc. Hospital/Nursing ManagementHealth Services MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education. MDA combats neuromuscular diseases through programs of worldwide research, comprehensive medical and support services, and far-reaching professional and public health education. With national headquarters in Tucson, MDA has more than 200 offices across the country, sponsors some 200 hospital-affiliated clinics and supports more than 330 research projects around the world. MDA supports more research on neuromuscular diseases than any other private-sector organization in the world. MDA scientists are in the forefront of gene therapy research and have uncovered the genetic defects responsible for several forms of muscular dystrophy, Charcot-Marie-Tooth disease, a form of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), childhood spinal muscular atrophy and several other neuromuscular conditions. The Association's comprehensive services program includes diagnostic and follow-up medical consultations, flu shots, support groups, MDA summer camps for youngsters, a medical equipment program, assistance with equipment repairs and resource referral. Through its national advocacy program, MDA works to make life better for people with muscular dystrophy and related muscle diseases by providing representation in matters of public policy and research advancement, nationally and internationally; and facilitating active involvement in these areas by the people it serves. MDA was created in 1950 by a group of adults with muscular dystrophy, parents of children with muscular dystrophy and a physician-scientist studying the disorder. Since its earliest days, it has been energized by its number-one volunteer and national chairman, entertainer Jerry Lewis. | Hospital/Nursing Management | Director/Board Member | |
| STAGEZERO LIFE SCIENCES LTD. | Medical Specialties | Comptroller/Controller/Auditor | |
Washington National Opera
 Washington National Opera Movies/EntertainmentConsumer Services Washington National Opera operates as an opera company. The company was founded in 1956 and is headquartered in Washington, DC. | Movies/Entertainment | President Director/Board Member | |
Wi2Wi, Inc.
 Wi2Wi, Inc. Specialty TelecommunicationsCommunications Wi2Wi, Inc. provides advanced microsystems, miniaturized embedded wireless connectivity solutions. Its products include wireless connectivity, timing and frequency control, and antennas and connectors. The company is headquartered in San Jose, CA. | Specialty Telecommunications | Director/Board Member Chairman | |
| Hemo-Stat Ltd. | President | ||
| Resolution Pharmaceuticals, Inc. | Chief Executive Officer Director of Finance/CFO | ||
| Canadian Biomaterials Society | President | ||
| The Aliments Soyummi, Inc. | Director/Board Member Chairman | ||
PlantForm Corp.
 PlantForm Corp. Pharmaceuticals: MajorHealth Technology PlantForm Corp. engages in a biopharmaceutical company. It focuses on the development and production of ntibody and protein drugs using manufacturing platform. The firm’s vivoXPRESS technology uses genetically modified tobacco plants to produce biopharmaceuticals in fully contained greenhouse environments. The company was founded by J. Christopher Hall, Mark Goldberg, Don Stewart, and Ronald G. Hosking in 2008 and is headquartered in Toronto, Canada. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| IMMUNE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Operating Officer | |
| WI2WI CORPORATION | Telecommunications Equipment | Director/Board Member Chairman | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| SATELLOS BIOSCIENCE INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Akashi Therapeutics Inc
 Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Pharmaceuticals: Major | Chief Executive Officer |
Statistics
International
| United States | 24 |
| Canada | 22 |
| United Kingdom | 3 |
| Bahamas | 2 |
| India | 2 |
Sectoral
| Health Technology | 18 |
| Consumer Services | 13 |
| Finance | 5 |
| Health Services | 4 |
| Non-Energy Minerals | 3 |
Operational
| Director/Board Member | 145 |
| Corporate Officer/Principal | 49 |
| Independent Dir/Board Member | 41 |
| Chairman | 39 |
| Founder | 30 |
Most connected contacts
| Insiders | |
|---|---|
| Michael R. Sonnenreich | 31 |
| Hans P. Black | 26 |
| William Wyman | 21 |
| George Adams | 18 |
| Jeff Wolf | 17 |
| Philippe Couillard | 17 |
| Mitchell Kaye | 16 |
| Edward Smith | 15 |
| Bill Lambert | 15 |
| Graham Strachan | 15 |
| Warren Whitehead | 14 |
| Eugene Williams | 13 |
| James Moodie Rae | 12 |
| Wen Hui Zhang | 12 |
| Elliot Goldstein | 10 |
- Stock Market
- Insiders
- Robert Gundel
- Company connections
